On this page
Dr Lal PathLabs to buy 70% of SN Genelab in genomics push
Our read
Dr Lal PathLabs is buying a genomics platform rather than just incremental revenue, positioning specialty diagnostics as a higher-value growth engine; the payoff depends on national referral-network commercialization and talent-led execution.
For operators
Dr Lal PathLabs can use SN Genelab’s genomics capabilities to deepen its advanced-testing menu, but must integrate specialized workflows and scale referrals across its national network.
Watch
Completion timing and final cash consideration versus the stated ₹168 crore upfront cap and ₹31.5 crore earn-out cap.
The report,
Dr Lal PathLabs approved acquisition of a 70% stake in Gujarat-based genomics diagnostics provider SN Genelab for up to ₹168 crore cash plus a ₹31.5 crore earn-out, aiming to expand advanced genomics diagnostic services.
- Cash consideration for 70% stakeUp to ₹168 crore
- Performance-linked earn-out cap₹31.5 crore
Reported figures
From the report. Source details below
| SN Genelab FY26 turnover: | ₹57.96 crore |
|---|---|
| SN Genelab FY25 turnover: | ₹53.36 crore |
| SN Genelab FY24 turnover: | ₹43.27 crore |
Why it matters to operators
The acquisition signals a targeted move into high-complexity genomics diagnostics, combining a regional specialist’s expertise with Dr Lal PathLabs’ distribution, brand and patient access.
What to watch next
- SN Genelab revenue growth, EBITDA trajectory and whether FY26 turnover growth sustains after acquisition closing.
- Retention of founders, pathologists, molecular biologists, bioinformaticians and key referring clinicians.
- Expansion of genomics test availability across Dr Lal's network, including test volumes, turnaround time and share of samples referred from outside Gujarat.
- Regulatory, accreditation and data-privacy compliance for genetic testing, sample handling and genomic-data reporting.
- Changes in specialty diagnostics mix, average realization per test and margin commentary in Dr Lal PathLabs' post-close earnings.
Show 1 more
- Competitive actions from Metropolis, SRL, Thyrocare, hospital chains and specialized genomics laboratories.
Likely next moves
Our read of what comes next — analysis, not reported by the source.
- Roll out SN Genelab's genomics panels through Dr Lal PathLabs' collection-center and B2B clinician network, initially in Gujarat and major metros.
- Integrate laboratory information systems, sample logistics, quality controls and reporting workflows while retaining key genomics scientists and medical specialists.
- Bundle genomic testing with oncology, prenatal, infertility, preventive-health and rare-disease diagnostic pathways to raise specialty-test attach rates.
- Use the performance-linked earn-out to prioritize revenue, turnaround-time, accreditation and profitability milestones before committing additional expansion capital.
- Evaluate further bolt-on acquisitions or partnerships in molecular diagnostics, bioinformatics, digital genetic counseling and hospital oncology networks if demand validates the platform strategy.